title: The feasibility of using concentrates containing factor IX for continuous infusion.
abstract: We have investigated the feasibility of continuous infusion of undiluted factor IX (F IX) over several days using minipumps. The stabilities of seven different reconstituted F IX products were substantially better than those declared by the manufacturers. Several concentrates maintained factor activities 80% of baseline for the entire period of 4 weeks at 4-8d̀C as did one product at 20-23d̀A. At 37d̀C the latter concentrate was stable for at least 1 week. The stability seemed to correlate with the purity of the product. Analysis of two prothrombin comples concentrates by gel electrophoresis demonstrated degradation of prothrombin to prethrombin-1 and fragment 1 at 37d̀C and in one of the concentrates also at 20-23d̀C. In two F IX concentrates the corresponding analysis did not reveal any degradation. Four patients were treated with continuous infusion with a pure F IX concentrate (Mononine™, Armour) after surgery or for serious haemorrhage (two each) with good haemostatic effect, an initial progressive decrease of the F IX clearance, and no side-effects. Continuous infusion with F IX, using a minipump and undiluted reconstituted factor, is therefore feasible and effective, and can be conveniently prepared for several days at a time. Pure F IX products are more stable and probably safer for this purpose.
authors.affiliation: The National Haemophilia Centre, Chaim Sheba Medical Centre, Tel Hashomer, Isreal, and Haemophilia Treatment Centre, University Hospital, Laikon Regional General Hospital of Athens, Greece.
authors.forename: S
authors.initials: S
authors.lastname: Schulman
authors.affiliation: The National Haemophilia Centre, Chaim Sheba Medical Centre, Tel Hashomer, Isreal, and Haemophilia Treatment Centre, University Hospital, Laikon Regional General Hospital of Athens, Greece.
authors.forename: S
authors.initials: S
authors.lastname: Gitel
authors.affiliation: The National Haemophilia Centre, Chaim Sheba Medical Centre, Tel Hashomer, Isreal, and Haemophilia Treatment Centre, University Hospital, Laikon Regional General Hospital of Athens, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Zivelin
authors.affiliation: The National Haemophilia Centre, Chaim Sheba Medical Centre, Tel Hashomer, Isreal, and Haemophilia Treatment Centre, University Hospital, Laikon Regional General Hospital of Athens, Greece.
authors.forename: O
authors.initials: O
authors.lastname: Katsarou
authors.affiliation: The National Haemophilia Centre, Chaim Sheba Medical Centre, Tel Hashomer, Isreal, and Haemophilia Treatment Centre, University Hospital, Laikon Regional General Hospital of Athens, Greece.
authors.forename: T
authors.initials: T
authors.lastname: Mandalaki
authors.affiliation: The National Haemophilia Centre, Chaim Sheba Medical Centre, Tel Hashomer, Isreal, and Haemophilia Treatment Centre, University Hospital, Laikon Regional General Hospital of Athens, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Varon
authors.affiliation: The National Haemophilia Centre, Chaim Sheba Medical Centre, Tel Hashomer, Isreal, and Haemophilia Treatment Centre, University Hospital, Laikon Regional General Hospital of Athens, Greece.
authors.forename: U
authors.initials: U
authors.lastname: Martinowitz
keywords: continuous infusion; factor IX; haemophilia B; stability; thrombogenicity